281 related articles for article (PubMed ID: 27372293)
21. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
22. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
[No Abstract] [Full Text] [Related]
23. A review of novel therapies for melanoma.
Karimkhani C; Gonzalez R; Dellavalle RP
Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
[TBL] [Abstract][Full Text] [Related]
24. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.
Elias EG; Zapas JL; McCarron EC; Beam SL; Hasskamp JH; Culpepper WJ
Cancer Biother Radiopharm; 2008 Jun; 23(3):285-91. PubMed ID: 18593361
[TBL] [Abstract][Full Text] [Related]
25. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
Elias EG; Zapas JL; Beam SL; Brown SD
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):15-8. PubMed ID: 15934495
[TBL] [Abstract][Full Text] [Related]
26. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
Spitler LE; Grossbard ML; Ernstoff MS; Silver G; Jacobs M; Hayes FA; Soong SJ
J Clin Oncol; 2000 Apr; 18(8):1614-21. PubMed ID: 10764421
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus oncolytic vaccine therapy in melanoma.
Sivendran S; Pan M; Kaufman HL; Saenger Y
Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
[TBL] [Abstract][Full Text] [Related]
29. OncoVEX
Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.
Cassaday RD; Sondel PM; King DM; Macklin MD; Gan J; Warner TF; Zuleger CL; Bridges AJ; Schalch HG; Kim KM; Hank JA; Mahvi DM; Albertini MR
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):540-9. PubMed ID: 17255276
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
[TBL] [Abstract][Full Text] [Related]
32. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic virus immunotherapy for melanoma.
Dharmadhikari N; Mehnert JM; Kaufman HL
Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
Locke F; Clark JI; Gajewski TF
Cancer Chemother Pharmacol; 2010 Feb; 65(3):509-14. PubMed ID: 19597729
[TBL] [Abstract][Full Text] [Related]
35. Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.
Spitler LE; Cao H; Piironen T; Whiteside TL; Weber RW; Cruickshank S
Am J Clin Oncol; 2017 Apr; 40(2):207-213. PubMed ID: 25286079
[TBL] [Abstract][Full Text] [Related]
36. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.
Hughes T; Coffin RS; Lilley CE; Ponce R; Kaufman HL
Oncolytic Virother; 2014; 3():11-20. PubMed ID: 27512660
[TBL] [Abstract][Full Text] [Related]
37. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma.
Tarhini AA; Joshi I; Garner F
Immunotherapy; 2021 Aug; 13(12):1011-1029. PubMed ID: 34157863
[TBL] [Abstract][Full Text] [Related]
38. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
40. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
